The 2016 Universal Access and Affordable Medicines Forum of the European Public Health Alliance.
Organised under the auspices of the Polish Permanent Representation to the EU.
Health is a fundamental universal right which relies on fair and equal access to medicines. Nevertheless, it appears that patients across Europe may suffer from lack of affordability of many life-saving medicines.
The programme will discuss the current situation of access to medicines in Europe, EU regulatory developments and explore policy recommendations for affordable medicines that serve public health needs and promote genuine innovation for all.
Join the discussion on Twitter using #HealthyInnovation!
Relive the event
Speakers and Moderators
Dr Deborah Cohen
Associate Editor, British Medical Journal (BMJ)
Head, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies
Juan José Rodríguez Sendín
President, General Medical Council of Spain (CGCOM)
Deputy Director-General & Head of Regulatory Affairs, Medicines For Europe
Director, Government affairs & Policy – EMEA, Gilead
Co-Director, Global Health Justice Partnership, Yale University & patient activist
Senior Lecturer, Department of Social Science, Health and Medicine, King’s College London,
Chairman, Drug Commission, German Medical Association – Member, Management Board, European Medicines Agency (EMA)
Secretary General, European Confederation of Pharmaceutical Enterpreneurs (EUCOPE)
International Development Advisor, Drugs for Neglected Diseases Initiative (DNDi)
Senior Health Economist, Belgian Health Care Knowledge Centre (KCE)
Director-General, European Organisation for Research and Treatment of Cancer (EORTC)
Director Public Policy for Europe and Canada, MSD
Director, Mario Negri Institute for Pharmacological Research
Head of Sector Health Technology Assessment, Unit Medicinal Products (B4), DG SANTE, European Commission
Director European Affairs, European Federation of Pharmaceutical Industries and Associations (EFPIA)
Marc Van de Casteele
Coordinator of pharmaceutical assessment, Belgian Institute for Health Insurance and Invalidity (RIZIV/INAMI)
Medical Innovation & Access Policy Adviser, Médecins Sans Frontières-Access Campaign